BACKGROUND: Congenital hyperinsulinism (CHI) is characterised by an over secretion of insulin by the pancreatic β-cells. This condition is mostly caused by mutations in ABCC8 or KCNJ11 genes encoding the SUR1 and KIR6.2 subunits of the ATP-sensitive potassium (K(ATP)) channel. CHI patients are classified according to their responsiveness to diazoxide and to their histopathological diagnosis (either focal, diffuse or atypical forms). Here, we raise the benefits/limits of the genetic diagnosis in the clinical management of CHI patients. METHODS: ABCC8/KCNJ11 mutational spectrum was established in 109 diazoxide-unresponsive CHI patients for whom an appropriate clinical management is essential to prevent brain damage. Relationships between genotype and radiopathological diagnosis were analysed. RESULTS: ABCC8 or KCNJ11 defects were found in 82% of the CHI cases. All patients with a focal form were associated with a single K(ATP) channel molecular event. In contrast, patients with diffuse forms were genetically more heterogeneous: 47% were associated with recessively inherited mutations, 34% carried a single heterozygous mutation and 19% had no mutation. There appeared to be a predominance of paternally inherited mutations in patients diagnosed with a diffuse form and carrying a sole K(ATP) channel mutation. CONCLUSIONS: The identification of recessively inherited mutations related to severe and diffuse forms of CHI provides an informative genetic diagnosis and allows prenatal diagnosis. In contrast, in patients carrying a single K(ATP) channel mutation, genetic analysis should be confronted with the PET imaging to categorise patients as focal or diffuse forms in order to get the appropriate therapeutic management.
BACKGROUND:Congenital hyperinsulinism (CHI) is characterised by an over secretion of insulin by the pancreatic β-cells. This condition is mostly caused by mutations in ABCC8 or KCNJ11 genes encoding the SUR1 and KIR6.2 subunits of the ATP-sensitive potassium (K(ATP)) channel. CHI patients are classified according to their responsiveness to diazoxide and to their histopathological diagnosis (either focal, diffuse or atypical forms). Here, we raise the benefits/limits of the genetic diagnosis in the clinical management of CHI patients. METHODS:ABCC8/KCNJ11 mutational spectrum was established in 109 diazoxide-unresponsive CHI patients for whom an appropriate clinical management is essential to prevent brain damage. Relationships between genotype and radiopathological diagnosis were analysed. RESULTS:ABCC8 or KCNJ11 defects were found in 82% of the CHI cases. All patients with a focal form were associated with a single K(ATP) channel molecular event. In contrast, patients with diffuse forms were genetically more heterogeneous: 47% were associated with recessively inherited mutations, 34% carried a single heterozygous mutation and 19% had no mutation. There appeared to be a predominance of paternally inherited mutations in patients diagnosed with a diffuse form and carrying a sole K(ATP) channel mutation. CONCLUSIONS: The identification of recessively inherited mutations related to severe and diffuse forms of CHI provides an informative genetic diagnosis and allows prenatal diagnosis. In contrast, in patients carrying a single K(ATP) channel mutation, genetic analysis should be confronted with the PET imaging to categorise patients as focal or diffuse forms in order to get the appropriate therapeutic management.
Authors: K E Snider; S Becker; L Boyajian; S-L Shyng; C MacMullen; N Hughes; K Ganapathy; T Bhatti; C A Stanley; A Ganguly Journal: J Clin Endocrinol Metab Date: 2012-12-28 Impact factor: 5.958
Authors: James T Bennett; Valeria Vasta; Min Zhang; Jaya Narayanan; Peter Gerrits; Si Houn Hahn Journal: Mol Genet Metab Date: 2014-12-20 Impact factor: 4.797
Authors: C Saint-Martin; Q Zhou; G M Martin; C Vaury; G Leroy; J-B Arnoux; P de Lonlay; S-L Shyng; C Bellanné-Chantelot Journal: Clin Genet Date: 2014-06-06 Impact factor: 4.438
Authors: G Alkorta-Aranburu; D Carmody; Y W Cheng; V Nelakuditi; L Ma; Jazzmyne T Dickens; S Das; S A W Greeley; D Del Gaudio Journal: Mol Genet Metab Date: 2014-09-28 Impact factor: 4.797
Authors: Dunia Ismail; Ritika R Kapoor; Virpi V Smith; Michael Ashworth; Oliver Blankenstein; Agostino Pierro; Sarah E Flanagan; Sian Ellard; Khalid Hussain Journal: J Clin Endocrinol Metab Date: 2011-10-26 Impact factor: 5.958
Authors: Ritika R Kapoor; Sarah E Flanagan; Ved Bhushan Arya; Julian P Shield; Sian Ellard; Khalid Hussain Journal: Eur J Endocrinol Date: 2013-03-15 Impact factor: 6.664
Authors: Michael S Bohnen; Lijiang Ma; Na Zhu; Hongjian Qi; Conor McClenaghan; Claudia Gonzaga-Jauregui; Frederick E Dewey; John D Overton; Jeffrey G Reid; Alan R Shuldiner; Aris Baras; Kevin J Sampson; Marta Bleda; Charaka Hadinnapola; Matthias Haimel; Harm J Bogaard; Colin Church; Gerry Coghlan; Paul A Corris; Mélanie Eyries; J Simon R Gibbs; Barbara Girerd; Arjan C Houweling; Marc Humbert; Christophe Guignabert; David G Kiely; Allan Lawrie; Rob V MacKenzie Ross; Jennifer M Martin; David Montani; Andrew J Peacock; Joanna Pepke-Zaba; Florent Soubrier; Jay Suntharalingam; Mark Toshner; Carmen M Treacy; Richard C Trembath; Anton Vonk Noordegraaf; John Wharton; Martin R Wilkins; Stephen J Wort; Katherine Yates; Stefan Gräf; Nicholas W Morrell; Usha Krishnan; Erika B Rosenzweig; Yufeng Shen; Colin G Nichols; Robert S Kass; Wendy K Chung Journal: Circ Genom Precis Med Date: 2018-10